AR125188A1 - Inhibidores del vmat2 y métodos de uso - Google Patents
Inhibidores del vmat2 y métodos de usoInfo
- Publication number
- AR125188A1 AR125188A1 ARP220100663A ARP220100663A AR125188A1 AR 125188 A1 AR125188 A1 AR 125188A1 AR P220100663 A ARP220100663 A AR P220100663A AR P220100663 A ARP220100663 A AR P220100663A AR 125188 A1 AR125188 A1 AR 125188A1
- Authority
- AR
- Argentina
- Prior art keywords
- c4alkyl
- membered heterocyclyl
- haloc1
- unsubstituted
- substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- -1 C1-C4alkylamino Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta divulgación se refiere generalmente a compuestos inhibidores de VMAT2, composiciones y métodos relacionados con ellos. Reivindicación 1: Un compuesto de fórmula (1), o una de sus sales farmacéuticamente aceptables, donde: R¹ es R²A, -(CH₂)ₘ-R²B, o -(CH₂)ₙ-OR²C; R²A es C₂-C₄alquenilo, C₁-C₆alquilo, C₃-C₈cicloalquilo, o heterociclilo de 4 - 7 miembros, cada uno, no sustituido o sustituido con uno o más RA; cada RA se selecciona de manera independiente del grupo que consiste en: C₁-C₄alcoxi, C₁-C₄alquilo, C₁-C₄alquilamino, C₁-C₄alquilosulfonilo, C₂-C₄dialquilamino, C₂-C₄dialquilosulfamoílo, halógeno, haloC₁-C₄alcoxi, haloC₁-C₄alquilo, haloC₂-C₄dialquilamino, heterociclilo de 4 - 7 miembros, -CN, -OH, y oxo; R²B es arilo, C₃-C₈cicloalquilo, heteroarilo de 5 - 10 miembros, o heterociclilo de 4 - 7 miembros, cada uno, no sustituido o sustituido con uno o más RB; cada RB se selecciona de manera independiente del grupo que consiste en: C₁-C₄alquilo, C₁-C₄alquilosulfonilo, C₁-C₄alquilosulfoniloxi, -CN, -CH₂CN, halógeno, haloC₁-C₄alquilo, haloC₁-C₄alquilosulfonilo, oxo, y -OH; R²C es C₁-C₄alquilo, C₃-C₈cicloalquilo, o heterociclilo de 4 - 7 miembros, cada uno, no sustituido o sustituido con uno o más RC; cada RC es de manera independiente -CN o C₃-C₆cicloalquilo; m es 0, 1, 2, 3, ó 4; y n es 1, 2, ó 3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164135P | 2021-03-22 | 2021-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125188A1 true AR125188A1 (es) | 2023-06-21 |
Family
ID=81325053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100663A AR125188A1 (es) | 2021-03-22 | 2022-03-21 | Inhibidores del vmat2 y métodos de uso |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11718618B2 (es) |
| EP (1) | EP4168409A1 (es) |
| JP (1) | JP2024511053A (es) |
| KR (1) | KR20230160308A (es) |
| CN (1) | CN117062815A (es) |
| AR (1) | AR125188A1 (es) |
| AU (1) | AU2022241988A1 (es) |
| BR (1) | BR112023016273A2 (es) |
| CA (1) | CA3207452A1 (es) |
| CL (1) | CL2023002785A1 (es) |
| CO (1) | CO2023012322A2 (es) |
| CR (1) | CR20230448A (es) |
| DO (1) | DOP2023000197A (es) |
| EC (1) | ECSP23070370A (es) |
| IL (1) | IL305054A (es) |
| MX (1) | MX2023010566A (es) |
| PE (1) | PE20240822A1 (es) |
| TW (1) | TW202304901A (es) |
| WO (1) | WO2022203984A1 (es) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3209005A (en) | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| AU2007248764B2 (en) | 2006-05-02 | 2013-08-01 | Avid Radiopharmaceuticals, Inc. | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| PT2081929E (pt) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
| US8008500B2 (en) | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US7897769B2 (en) | 2007-10-25 | 2011-03-01 | General Electric Company | Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes |
| US7910738B2 (en) | 2007-11-29 | 2011-03-22 | General Electric Company | Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| US8053578B2 (en) * | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| US7902364B2 (en) | 2007-11-29 | 2011-03-08 | General Electric Company | Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| US8013161B1 (en) | 2007-12-07 | 2011-09-06 | General Electric Company | Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes |
| US7919622B2 (en) | 2007-12-07 | 2011-04-05 | Kande Kankanamalage Dayarathna Amarasinghe | Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| ES2896678T3 (es) | 2008-09-18 | 2022-02-25 | Auspex Pharmaceuticals Inc | Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2 |
| WO2011153157A2 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| EP2836241B1 (en) | 2012-04-10 | 2019-02-20 | Lantheus Medical Imaging, Inc. | Radiopharmaceutical synthesis methods |
| CN116768882A (zh) | 2012-09-18 | 2023-09-19 | 奥斯拜客斯制药有限公司 | 化合物、及其药物组合物及治疗方法 |
| CA2896202A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
| JP2016506957A (ja) | 2013-01-31 | 2016-03-07 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｖｍａｔ２のベンゾキノロン阻害剤 |
| WO2014144064A2 (en) | 2013-03-15 | 2014-09-18 | University Of Kentucky Research Foundation | 1,4-disubstituted piperidines, 1,4-disubstituted piperazines, 1,4-disubstituted diazepanes, and 1,3-disubstituted pyrrolidine compounds |
| GB201313291D0 (en) | 2013-07-25 | 2013-09-11 | Ge Healthcare Ltd | Imaging neurological disease |
| WO2015077521A1 (en) | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3398602A1 (en) | 2014-01-27 | 2018-11-07 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CN107438606B (zh) | 2015-02-06 | 2020-09-18 | 纽罗克里生物科学有限公司 | [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法 |
| EP3394057B1 (en) | 2015-12-23 | 2022-03-30 | Neurocrine Biosciences, Inc. | Synthetic method for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| US11999676B2 (en) | 2016-04-21 | 2024-06-04 | University Of Kentucky Research Foundation | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse |
| US10668030B2 (en) | 2016-04-21 | 2020-06-02 | University Of Kentucky Research Foundation | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| TW201906818A (zh) | 2017-05-31 | 2019-02-16 | 美商５１１製藥公司 | 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用 |
| EP3706748A4 (en) | 2017-11-08 | 2021-08-11 | Foresee Pharmaceuticals Co., Ltd. | ESTER OF DIHYDROTETRABENAZINE |
| WO2020086765A1 (en) | 2018-10-24 | 2020-04-30 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| US20220340562A1 (en) | 2019-08-12 | 2022-10-27 | Shandong Luye Pharmaceutical Co., Ltd. | Vmat2 inhibitor and preparation method therefor and application thereof |
| US20210087191A1 (en) | 2020-12-04 | 2021-03-25 | Dispersol Technologies, Llc | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| IL310907A (en) | 2021-08-20 | 2024-04-01 | Neurocrine Biosciences Inc | Screening methods for VMAT2 inhibitors |
-
2022
- 2022-03-21 JP JP2023557361A patent/JP2024511053A/ja active Pending
- 2022-03-21 WO PCT/US2022/021080 patent/WO2022203984A1/en active Application Filing
- 2022-03-21 CA CA3207452A patent/CA3207452A1/en active Pending
- 2022-03-21 EP EP22715479.6A patent/EP4168409A1/en active Pending
- 2022-03-21 CN CN202280023462.8A patent/CN117062815A/zh active Pending
- 2022-03-21 BR BR112023016273A patent/BR112023016273A2/pt unknown
- 2022-03-21 CR CR20230448A patent/CR20230448A/es unknown
- 2022-03-21 KR KR1020237035676A patent/KR20230160308A/ko unknown
- 2022-03-21 TW TW111110403A patent/TW202304901A/zh unknown
- 2022-03-21 MX MX2023010566A patent/MX2023010566A/es unknown
- 2022-03-21 AU AU2022241988A patent/AU2022241988A1/en active Pending
- 2022-03-21 PE PE2023002681A patent/PE20240822A1/es unknown
- 2022-03-21 IL IL305054A patent/IL305054A/en unknown
- 2022-03-21 AR ARP220100663A patent/AR125188A1/es unknown
-
2023
- 2023-01-12 US US18/096,073 patent/US11718618B2/en active Active
- 2023-06-09 US US18/207,807 patent/US20240010647A1/en active Pending
- 2023-09-18 CO CONC2023/0012322A patent/CO2023012322A2/es unknown
- 2023-09-18 DO DO2023000197A patent/DOP2023000197A/es unknown
- 2023-09-18 EC ECSENADI202370370A patent/ECSP23070370A/es unknown
- 2023-09-20 CL CL2023002785A patent/CL2023002785A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11718618B2 (en) | 2023-08-08 |
| IL305054A (en) | 2023-10-01 |
| PE20240822A1 (es) | 2024-04-18 |
| JP2024511053A (ja) | 2024-03-12 |
| EP4168409A1 (en) | 2023-04-26 |
| US20240010647A1 (en) | 2024-01-11 |
| MX2023010566A (es) | 2023-09-21 |
| CL2023002785A1 (es) | 2024-02-02 |
| KR20230160308A (ko) | 2023-11-23 |
| ECSP23070370A (es) | 2023-10-31 |
| CR20230448A (es) | 2023-10-27 |
| US20230159528A1 (en) | 2023-05-25 |
| TW202304901A (zh) | 2023-02-01 |
| DOP2023000197A (es) | 2023-11-15 |
| CN117062815A (zh) | 2023-11-14 |
| WO2022203984A1 (en) | 2022-09-29 |
| CA3207452A1 (en) | 2022-09-29 |
| CO2023012322A2 (es) | 2023-10-09 |
| AU2022241988A1 (en) | 2023-10-12 |
| BR112023016273A2 (pt) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009225A2 (es) | Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco | |
| AR114244A1 (es) | Compuestos que degradan efgr útiles en el tratamiento del cáncer | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| PE20170774A1 (es) | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos | |
| RS50540B (sr) | Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
| RS53059B (en) | NEW SUBSTITUTED IMIDAZOCHINOLINES | |
| AR071739A1 (es) | Inhibidores de transcriptasa reversa | |
| CO5390047A1 (es) | Derivados de uk-2a | |
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| CO5550398A2 (es) | 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos | |
| WO2006109075A3 (en) | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| CO6220970A2 (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos | |
| AR109650A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| DK1117297T3 (da) | Syntetiske analoger af ecteinascidin-743 | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. | |
| AR114338A1 (es) | Herbicidas de carboxilato de piridina y pirimidina y métodos para su uso | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| RU2016137356A (ru) | Соединение нафтиламида, способ его получения и применение |